By Rupa Palanki On September 20, the Federal Trade Commission (FTC) filed a landmark lawsuit against the three largest prescription drug benefit managers (PBMs) — Caremark Rx, Express Scripts, and OptumRx — and their affiliated group purchasing organizations. The FTC alleges that these entities engaged in “anticompetitive and unfair rebating practices,” artificially increasing insulin drug…
by Daniela Cepeda Cuadrado There is a wealth of research demonstrating that corruption — the abuse of entrusted power for private gain — has contributed to weakening health systems and worsening public health globally. Corruption is associated with a higher infant mortality rate, the rise of antimicrobial resistance, and the diversion of key resources to…
Funding for psychedelic research may increasingly rely on nonprofit and commercial partnerships.
Reasonable pricing clauses are needed to ensure that American taxpayers receive a fairer return on their investment for essential therapies.
Past 340B litigation highlights that takings challenges to the Medicare price negotiation program face an uphill battle.
By Matthew Chun In recent months, generative artificial intelligence (AI) has taken the world by storm. AI systems like ChatGPT and Stable Diffusion have captured the imagination of the masses with their impressive and sometimes controversial ability to generate human-like text and artwork. However, it may come as a surprise to some that — in…
The Truth Pill is a monumental work that convincingly shows that drug regulation is but a myth in India.
Private sector employers should reconsider the implications of a blanket prohibition on workplace use of controlled substances.
People who microdose psychedelics claim that it provides a very wide range of benefits. Is it just a placebo effect?
We are excited to welcome our inaugural group of affiliated researchers for the Project on Psychedelics Law and Regulation (POPLAR).
